Abstract

BackgroundPrevious studies have reported that pretreatment thrombocytosis is associated with poor outcomes in several cancer types. This study was designed to evaluate the prognostic significance of preoperative thrombocytosis in patients with non-small cell lung cancer (NSCLC) who undergo surgery.MethodsWe retrospectively reviewed the records of 199 patients who underwent R0 resection for NSCLC between May 2003 and July 2006 at Seoul National University Bundang Hospital, Seongnam, Korea.ResultsThe frequency of preoperative thrombocytosis was 7.5% (15/199). Patients with preoperative thrombocytosis had shorter overall survival (OS, P = 0.003) and disease-free survival (DFS, P = 0.005) than those without thrombocytosis. In multivariable analysis, patients with preoperative thrombocytosis had a significantly greater risk of death and recurrence than those without preoperative thrombocytosis (risk of death: hazard ratio (HR) 2.98, 95% confidence interval (CI) 1.39 to 6.37, P = 0.005; risk of recurrence: HR 2.47, 95% CI 1.22 to 5.01, P = 0.012). A tendency towards a shorter OS and DFS was observed in three patients with persistent thrombocytosis during the follow-up period when compared with those of patients who recovered from thrombocytosis after surgery.ConclusionsPreoperative thrombocytosis was valuable for predicting the prognosis of patients with NSCLC. Special attention should be paid to patients with preoperative and postoperative thrombocytosis.

Highlights

  • Previous studies have reported that pretreatment thrombocytosis is associated with poor outcomes in several cancer types

  • The most important prognostic factor for non-small cell lung cancer (NSCLC) is tumor stage, with advanced stage disease being associated with the poorest prognosis

  • Our findings demonstrated that preoperative thrombocytosis in patients with resectable NSCLC was significantly associated with an increased risk of death and disease recurrence

Read more

Summary

Introduction

Previous studies have reported that pretreatment thrombocytosis is associated with poor outcomes in several cancer types. This study was designed to evaluate the prognostic significance of preoperative thrombocytosis in patients with non-small cell lung cancer (NSCLC) who undergo surgery. Lung cancer is the most common cause of cancerrelated death worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. There are several known prognostic factors for patients with NSCLC. The most important prognostic factor for NSCLC is tumor stage, with advanced stage disease being associated with the poorest prognosis. Several studies have shown the relationship of pretreatment

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call